Estuary Biotherapeutics
Agent43Agent Readiness: 43/100. Above median. Measured by StartupHub.ai. Median 41.Trust61Data Trust: 61/100. Above median. Measured by StartupHub.ai. Median 61.Biotechnology company developing genetic medicines for patients with serious kidney diseases, focusing on autosomal dominant polycystic kidney disease (ADPKD).
About
Estuary Biotherapeutics is a biotechnology company focused on developing genetic medicines for patients with serious kidney diseases. Their lead programs, EST-201 and EST-101, are gene therapies targeting the root cause of autosomal dominant polycystic kidney disease (ADPKD), the most common inherited kidney disease. The company aims to bring these therapies into clinical trials to transform the course of the disease for patients.
Key facts
At-a-glance profile data
- Website
- estuarybio.com
- Headquarters
- Menlo Park, United States
- Founded
- 2022
- Total funding
- $93M (Series A)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 15 Oct 2026 | Series A | $93M | RA Capital |
Tech stack
Detected on estuarybio.com, last scanned 16 Oct 2026. Run your own scan
- Frontend
- Next.js
- Analytics
- Google Analytics 4
- CDN
- Vercel
- Email provider
- Google Workspace
Frequently asked
Is Estuary Biotherapeutics trustworthy and reputable?
StartupHub's Data Trust & Reputation score for Estuary Biotherapeutics is 61 out of 100, based on site security posture and privacy practices.
How much funding has Estuary Biotherapeutics raised?
Estuary Biotherapeutics has raised a total of $93M in funding. The most recent round on record is Series A.